A proposed new federal law could provide some competitive guardrails for the company's most important product.

By Rishika Sadam Dec 12 (Reuters) - Novo Nordisk launched Ozempic in India on Friday, pricing the 0.25 mg dose at $24.35 per ...

It continues to be pounded by competition and challenges coming from numerous directions.

Data from Structure Therapeutics and WAVE Life Sciences show that threats to the incumbents’ dominance are on the way.

The slump has virtually wiped out several years of stellar gains that came after Novo’s Wegovy drug was approved as a ...

In early December 2025, Novo Nordisk reported phase 3 Evoke and Evoke+ trial results showing oral semaglutide did not improve ...

In an interview, Novo Nordisk India’s managing director Vikrant Shrotriya discusses the launch of Ozempic, the company’s ...

By Rishika Sadam and Kashish Tandon Dec 12 (Reuters) - Novo Nordisk launched Ozempic in India on Friday, pricing the 0.25 mg ...

Dec 2 (Reuters) - Wegovy maker Novo Nordisk is planning to test its experimental obesity drug, CagriSema, in overweight ...

FDA may expedite approval timeline for Eli Lilly's weight-loss treatment, potentially moving decision date to late March from ...

EMA issues positive opinion on Novo Nordisk's higher-dose Wegovy, supported by strong weight-loss data and ongoing reviews in ...

Novo Nordisk A/S (NYSE:NVO) is among the cheap healthcare stocks to buy heading into 2026. On December 5, Kerry Holford, an ...